184 related articles for article (PubMed ID: 38123592)
1. Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells.
Zhang Y; Fang H; Wang G; Yuan G; Dong R; Luo J; Lyu Y; Wang Y; Li P; Zhou C; Yin W; Xiao H; Sun J; Zeng X
Nat Commun; 2023 Dec; 14(1):8491. PubMed ID: 38123592
[TBL] [Abstract][Full Text] [Related]
2. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.
Hu X; Manner K; DeJesus R; White K; Gattis C; Ngo P; Bandoro C; Tham E; Chu EY; Young C; Wells F; Basco R; Friera A; Kangeyan D; Beauchesne P; Dowdle WE; Deuse T; Fry TJ; Foster AE; Schrepfer S
Nat Commun; 2023 Apr; 14(1):2020. PubMed ID: 37037829
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
Jacoby E; Yang Y; Qin H; Chien CD; Kochenderfer JN; Fry TJ
Blood; 2016 Mar; 127(10):1361-70. PubMed ID: 26660684
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
7. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
8. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
9. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
Lv Z; Luo F; Chu Y
Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation.
Satake A; Schmidt AM; Nomura S; Kambayashi T
PLoS One; 2014; 9(3):e92888. PubMed ID: 24658577
[TBL] [Abstract][Full Text] [Related]
11. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
12. Paving the way towards universal treatment with allogenic T cells.
Townsend MH; Bennion K; Robison RA; O'Neill KL
Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
[TBL] [Abstract][Full Text] [Related]
13. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
14. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
Martínez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes.
Contassot E; Robinet E; Angonin R; Laithier V; Bittencourt M; Pavy JJ; Cahn JY; Hervé P; Tiberghien P
Bone Marrow Transplant; 1998 Dec; 22(11):1097-102. PubMed ID: 9877273
[TBL] [Abstract][Full Text] [Related]
17. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
Zhu D; Cardenas ME; Heitman J
Mol Pharmacol; 1996 Sep; 50(3):506-11. PubMed ID: 8794888
[TBL] [Abstract][Full Text] [Related]
19. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
20. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
Aparicio C; Acebal C; González-Vallinas M
Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
